Methoxsalen Maco Pharma (Methoxsalen)

Methoxsalen intercalates into DNA and, when activated by UVA light, forms covalent bonds with pyrimidine bases. These DNA cross‑links inhibit replication and transcription, leading to cell‑cycle arrest and apoptosis. The photochemical reaction also modulates local immune responses, reducing inflammation in treated skin areas.

The dosage of methoxsalen is individualized and determined by the prescribing healthcare professional based on the specific indication, patient characteristics, and the planned UVA exposure protocol. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Methoxsalen is classified as Pregnancy Category D, indicating evidence of fetal risk, and it is contraindicated during pregnancy. It is also excreted in breast milk, so breastfeeding is not recommended while using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Methoxsalen Maco Pharma. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to methoxsalen is another psoralen, 8‑methoxypsoralen (trioxsalen), which has a similar mechanism but may differ in pharmacokinetics and skin‑sensitisation profile. Compared with UVA therapy alone, methoxsalen enhances the therapeutic effect, allowing lower UVA doses to achieve comparable clinical outcomes.

Methoxsalen should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and avoid exposure to excessive heat or direct sunlight to maintain product stability.

Methoxsalen is administered for extracorporeal use, typically as an oral dose taken a few hours before a controlled UVA exposure session. The timing and amount are coordinated by the treating physician to ensure optimal activation of the drug during phototherapy.

Serious risks include severe phototoxic burns, blistering, and an increased long‑term risk of skin cancers such as squamous cell carcinoma or melanoma. Hepatic dysfunction and rare severe allergic reactions (anaphylaxis) may also occur. Patients should report any unexpected skin changes or systemic symptoms promptly.

Methoxsalen should be avoided in pregnant women, breastfeeding mothers, patients with known hypersensitivity to psoralens, individuals with severe renal or hepatic impairment without dose adjustment, and those taking other strong photosensitising agents unless closely monitored by a physician.